CompanyGraph
China Resources Double Crane Pharmaceutical Co., Ltd.
600062 · SSE · China
dcpc.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.5B, above the global median of $1.15B
- FinancialsAltman Z-Score 4.4: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.34%Below 5Y avg (2.42%)
Annual Rate
CNY 0.38Paid annual
Payout Ratio
30.0%Sustainable
Payback Period
41.3 yr
Last Ex-Dividend
Jul 28, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
16.84BCNY2.50B · vs all stocks (USD)
Trailing P/E
10.32xRevenue (TTM)
10.73BCNY1.59B · vs all stocks (USD)
Profit Margin
15.15%Beta
-0.0720xvs all stocks
52-Week Change
-20.30%vs all stocks
Market Capitalization
16.84BCNY2.50B · vs all stocks (USD)
Enterprise Value
15.88BCNY2.36B · vs all stocks (USD)
Trailing P/E
10.32xForward P/E
8.72xPEG Ratio
-2.14xPrice to Sales (TTM)
1.57xPrice to Book (MRQ)
1.38xEnterprise to Revenue
1.48xEnterprise to EBITDA
6.59xGross Margin
59.03%Profit Margin
15.15%Operating Margin
19.88%Return on Assets (TTM)
5.85%Return on Equity (TTM)
13.49%Revenue (TTM)
10.73BCNY1.59B · vs all stocks (USD)
Revenue per Share (TTM)
10.38CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-8.80%Gross Profit (TTM)
6.13BCNY911.10M · vs all stocks (USD)
EBITDA (TTM)
2.80BCNY415.45M · vs all stocks (USD)
Net Income (TTM)
1.63BCNY241.37M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-4.30%Operating Cash Flow (TTM)
1.34BCNY199.47M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
129.00MCNY19.16M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.3790CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
2.34%vs all stocks
5-Year Average Dividend Yield
2.42%vs all stocks
Payout Ratio
30.05%Minority Interest (Equity)
866.18MCNYFY2025 · Dec 31, 2025Revenue
11.00BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
4.62BCNYFY2025 · Dec 31, 2025Gross Profit
6.38BCNYFY2025 · Dec 31, 2025Operating Income
1.79BCNY266.30M · vs all stocks (USD)
Pre-tax Income
1.91BCNYFY2025 · Dec 31, 2025Income Tax Expense
227.52MCNYFY2025 · Dec 31, 2025Net Income
1.68BCNYFY2025 · Dec 31, 2025EBIT
1.94BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.80BCNYFY2025 · Dec 31, 2025Research & Development
531.60MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
2.30BCNYFY2025 · Dec 31, 2025Other Operating Expenses
153.03MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
26.66MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
33.58MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.59CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.59CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.03BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.03BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.68BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-36.27MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
1.04BCNYFY2025 · Dec 31, 2025Free Cash Flow
521.46MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.91BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.68BCNYFY2025 · Dec 31, 2025Other Non-cash Items
19.01MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-590.27MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-74.16MCNYFY2025 · Dec 31, 2025Capital Expenditures
-516.34MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.20BCNYFY2025 · Dec 31, 2025Sale of Investments
830.69MCNYFY2025 · Dec 31, 2025Other Investing Activity
-157.15MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.05BCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
154.49MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-179.13MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-716.05MCNYFY2025 · Dec 31, 2025Other Financing Charges
-625.83MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.37BCNYFY2025 · Dec 31, 2025Shares Outstanding
1.04BSharesUpdated Aug 20, 2026Float Shares
400.09MSharesUpdated Aug 20, 2026% Held by Insiders
62.18%vs all stocks
% Held by Institutions
2.88%vs all stocks
Total Cash (MRQ)
3.07BCNY456.08M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.97CNYUpdated Aug 20, 2026Total Debt (MRQ)
1.69BCNY250.76M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1298xCurrent Ratio (MRQ)
2.67xBook Value per Share (MRQ)
11.73CNYUpdated Aug 20, 2026Total Assets
17.01BCNY2.53B · vs all stocks (USD)
Total Current Assets
7.11BCNYFY2025 · Dec 31, 2025Total Liabilities
4.51BCNYFY2025 · Dec 31, 2025Total Non-current Assets
9.90BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.49BCNYFY2025 · Dec 31, 2025Total Current Liabilities
3.02BCNYFY2025 · Dec 31, 2025Cash
1.91BCNYFY2025 · Dec 31, 2025Cash Equivalents
6.73MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.91BCNYFY2025 · Dec 31, 2025Other Short-term Investments
500.87MCNYFY2025 · Dec 31, 2025Accounts Receivable
2.03BCNYFY2025 · Dec 31, 2025Inventory
1.58BCNYFY2025 · Dec 31, 2025Accounts Payable
668.98MCNYFY2025 · Dec 31, 2025Short-term Debt
143.78MCNYFY2025 · Dec 31, 2025Other Current Liabilities
76.53MCNYFY2025 · Dec 31, 2025Long-term Debt
1.05BCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
1.20MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.04BCNYFY2025 · Dec 31, 2025Retained Earnings
10.36BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
12.50BCNY1.86B · vs all stocks (USD)
Treasury Stock
34.02MCNYFY2025 · Dec 31, 202552-Week Low
15.29CNYUpdated Aug 20, 202652-Week High
20.50CNYUpdated Aug 20, 202652-Week Change
-20.30%vs all stocks
Beta
-0.0720xvs all stocks
50-Day MA
16.59CNYUpdated Aug 20, 2026200-Day MA
17.85CNYUpdated Aug 20, 2026Avg 10-Day Volume
11.16MSharesUpdated Aug 20, 2026Avg 30-Day Volume
11.29MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
1.57CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.4: safe zoneNotable
Altman Z-Score: 4.40
High earnings qualityNotable
Earnings Quality Score: 0.54
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.5B, above the global median of $1.15BNotable
Market cap (USD): 2,500,396,950.146Global Median: 1,146,734,693.424
Revenue is $1.59B, above the global median of $520.53MNotable
Revenue (USD): 1,593,421,643.039Global Median: 520,528,949.311
Levered free cash flow is $19.16M, above the global median of $16.24MNotable
Levered free cash flow (USD): 19,159,451.894Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
ApicHope Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Curaleaf Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Regencell Bioscience Holdings Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Dongbao Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Immunome Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
HUTCHMED
Tier 1ProductionApproval-Gated PipelineRule
Shandong Buchang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GN Store Nord A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
TransMedics Group Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow